A small-cap Constellation Brands.

A diversified beverage producer, like a startup Boston Beer Company.

• SALT Naturally Flavored Tequila: Flavored tequilas.
• TapouT Performance: A hydration and recovery isotonic sport drink.
• Copa di Vino: Wine products.
• Pulpoloco Sangria: Sangria products.
• qplash.com: An online platform for selling beverages and groceries.

The key risks for Endovia Health Sciences (symbol: EDVA) are primarily related to its significant financial distress, the inherent uncertainties of drug development and regulatory approval in its new cannabinoid health sciences focus, and its heavy reliance on external capital to fund operations and product development.

1. Financial Distress and Going Concern Issues: Endovia Health Sciences is facing severe financial challenges, including recurring operating losses and negative cash flows. In 2025, the company reported a net loss of $25.3 million. As of June 30, 2026, its cash and cash equivalents amounted to only $242,702, which is deemed insufficient to cover 12 months of operations. Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to its working capital deficit and liquidity risks. The company's revenue has sharply declined, and its financial statements indicate severe stress with large net losses and negative equity.
2. Regulatory Risks and Uncertainty in Cannabinoid Drug Development: Endovia Health Sciences has transitioned its business focus to a cannabinoid health sciences platform, concentrating on pharmaceutical, wellness, and veterinary cannabinoid products. This pivot involves navigating complex FDA regulatory pathways for the development and commercialization of its cannabinoid-based therapies, such as CannEpil® for drug-resistant epilepsy and veterinary applications. The process of obtaining FDA approval for new drugs is lengthy, expensive, and uncertain, posing significant risks regarding the company's ability to complete necessary studies and secure regulatory authorization for its products.
3. Dependence on External Capital and Potential for Dilution: The company is highly reliant on raising external capital to fund its ongoing operations and product development initiatives, particularly for its CannEpil® program, which requires at least $2 million over the next 12 months. Endovia Health Sciences is utilizing an equity line of credit (ELOC) to secure up to $30.8 million in gross proceeds; however, the actual amount received is contingent on share sales and market price. This dependence on external financing, including dilutive equity arrangements, poses a significant risk for existing shareholders due to potential share dilution. The company's forward-looking statements explicitly highlight risks related to its ability to raise capital and meet contractual obligations.

Here are clear emerging threats for Splash Beverage Group, Inc. (EDVA):

• The accelerating "better-for-you" trend across all beverage categories: Consumers are increasingly demanding natural ingredients, lower sugar content, and functional benefits from their drinks. This trend has led to a proliferation of new brands specifically targeting health-conscious consumers. Splash Beverage Group's existing portfolio, particularly flavored tequilas, wines, and sangrias, may face challenges if they are not perceived as aligning with these evolving health and wellness preferences, potentially making them less competitive against newer, more agile brands built around these principles.
• The growing "sober curious" movement and the rise of sophisticated non-alcoholic alternatives: There is a discernible and accelerating cultural shift, particularly among younger demographics, towards reducing or abstaining from alcohol consumption. This has fueled a booming market for high-quality non-alcoholic spirits, wines, beers, and ready-to-drink options. As a company with a significant portion of its portfolio in alcoholic beverages (flavored tequilas, wine, sangria), this movement represents a direct threat to the demand for their core products by potentially shrinking the overall market for traditional alcoholic drinks and offering increasingly appealing substitutes.

Share Issuance

• The company plans to issue approximately 54.4 million shares of common and preferred stock as part of the Medterra CBD, LLC acquisition, valued at $37.6 million.
• In 2025, shareholders approved an increase in authorized common shares to 400 million.
• Debt conversions and asset acquisitions in 2025 involved share issuances to reshape the balance sheet.

Inbound Investments

• Endovia Health Sciences (formerly Splash Beverage Group) has faced severe liquidity challenges, indicating a dependence on new financing for its operations.
• New funding and capital raises were undertaken in 2024 to support growth plans.

Outbound Investments

• The company is pursuing the acquisition of Medterra CBD, LLC, valued at $37.6 million, which includes the repayment of approximately $10.4 million of Medterra debt and additional cash for Medterra investors' taxes.
• Splash Beverage Group invested in Avicanna, a cannabinoid biopharmaceutical platform, as part of its strategic shift towards cannabinoid healthcare.
• A previously planned $20 million deal for Costa Rica water assets was rescinded prior to December 31, 2025.

Capital Expenditures

• The company estimates requiring at least $2 million in working capital, an additional $500,000 to develop its Chispo Tequila brand, and approximately $3 million for broader operating needs to revive beverage revenues.
• Operations effectively stalled after early 2025 due to a lack of capital, suggesting minimal capital expenditures during that period.